Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.